The MHRA has approved trofolastat to identify how far high-risk prostate cancer has spread before treatment, to detect ...

A new case report was published in Oncoscience's Volume 12 on March 31, 2025, titled "Cystadenofibroma and contralateral collision lesions: A unique ovarian case report." Authored by Dr. Naina ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with ...

In a world first, the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved trofolastat to detect cancerous lesions in men with prostate cancer Prostate cancer is one of the most ...

Diagnostic imaging plays an important role in identifying cancerous areas, which may help guide treatment decisions. Trofolastat is combined with the radioactive tracer technetium-99m to form ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA)-targeting agent for detecting ...

Image credit: Dave Hoeek via Shutterstock The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA ...